LGND Quote, Financials, Valuation and Earnings

Inspire Medical Systems, Inc. has a net margin of 10.18% compared to Ligand Pharmaceuticals, Inc.'s net margin of 4.42%. Ligand Pharmaceuticals, Inc.'s return on equity of 5.72% beat Inspire Medical Systems, Inc.'s return on equity of 6.62%.

Ligand Pharmaceuticals, Inc. has a consensus price target of $243.44, signalling upside risk potential of 21.52%. On the other hand Inspire Medical Systems, Inc. has an analysts' consensus of $140.00 which suggests that it could grow by 45.02%. Given that Inspire Medical Systems, Inc. has higher upside potential than Ligand Pharmaceuticals, Inc., analysts believe Inspire Medical Systems, Inc. is more attractive than Ligand Pharmaceuticals, Inc..

Ligand Pharmaceuticals, Inc. has a beta of 1.026, which suggesting that the stock is 2.587% more volatile than S&P 500. In comparison Inspire Medical Systems, Inc. has a beta of 0.696, suggesting its less volatile than the S&P 500 by 30.412%.

Ligand Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Inspire Medical Systems, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ligand Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Inspire Medical Systems, Inc. pays out -- of its earnings as a dividend.

Ligand Pharmaceuticals, Inc. quarterly revenues are $115.5M, which are smaller than Inspire Medical Systems, Inc. quarterly revenues of $224.5M. Ligand Pharmaceuticals, Inc.'s net income of $117.3M is higher than Inspire Medical Systems, Inc.'s net income of $9.9M. Notably, Ligand Pharmaceuticals, Inc.'s price-to-earnings ratio is 96.42x while Inspire Medical Systems, Inc.'s PE ratio is 66.22x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ligand Pharmaceuticals, Inc. is 15.69x versus 3.29x for Inspire Medical Systems, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of 10.18% compared to Ligand Pharmaceuticals, Inc.'s net margin of 21.47%. Ligand Pharmaceuticals, Inc.'s return on equity of 5.72% beat Johnson & Johnson's return on equity of 33.27%.

Ligand Pharmaceuticals, Inc. has a consensus price target of $243.44, signalling upside risk potential of 21.52%. On the other hand Johnson & Johnson has an analysts' consensus of $209.29 which suggests that it could grow by 1.42%. Given that Ligand Pharmaceuticals, Inc. has higher upside potential than Johnson & Johnson, analysts believe Ligand Pharmaceuticals, Inc. is more attractive than Johnson & Johnson.

Ligand Pharmaceuticals, Inc. has a beta of 1.026, which suggesting that the stock is 2.587% more volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.357, suggesting its less volatile than the S&P 500 by 64.296%.

Ligand Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 2.49% to investors and pays a quarterly dividend of $1.30 per share. Ligand Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Johnson & Johnson pays out 84.8% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Ligand Pharmaceuticals, Inc. quarterly revenues are $115.5M, which are smaller than Johnson & Johnson quarterly revenues of $24B. Ligand Pharmaceuticals, Inc.'s net income of $117.3M is lower than Johnson & Johnson's net income of $5.2B. Notably, Ligand Pharmaceuticals, Inc.'s price-to-earnings ratio is 96.42x while Johnson & Johnson's PE ratio is 19.92x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ligand Pharmaceuticals, Inc. is 15.69x versus 5.43x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Krystal Biotech, Inc. has a net margin of 10.18% compared to Ligand Pharmaceuticals, Inc.'s net margin of 81.15%. Ligand Pharmaceuticals, Inc.'s return on equity of 5.72% beat Krystal Biotech, Inc.'s return on equity of 19.91%.

Ligand Pharmaceuticals, Inc. has a consensus price target of $243.44, signalling upside risk potential of 21.52%. On the other hand Krystal Biotech, Inc. has an analysts' consensus of $229.00 which suggests that it could fall by -4.9%. Given that Ligand Pharmaceuticals, Inc. has higher upside potential than Krystal Biotech, Inc., analysts believe Ligand Pharmaceuticals, Inc. is more attractive than Krystal Biotech, Inc..

Ligand Pharmaceuticals, Inc. has a beta of 1.026, which suggesting that the stock is 2.587% more volatile than S&P 500. In comparison Krystal Biotech, Inc. has a beta of 0.485, suggesting its less volatile than the S&P 500 by 51.528%.

Ligand Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Krystal Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ligand Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Krystal Biotech, Inc. pays out -- of its earnings as a dividend.

Ligand Pharmaceuticals, Inc. quarterly revenues are $115.5M, which are larger than Krystal Biotech, Inc. quarterly revenues of $97.8M. Ligand Pharmaceuticals, Inc.'s net income of $117.3M is higher than Krystal Biotech, Inc.'s net income of $79.4M. Notably, Ligand Pharmaceuticals, Inc.'s price-to-earnings ratio is 96.42x while Krystal Biotech, Inc.'s PE ratio is 36.12x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ligand Pharmaceuticals, Inc. is 15.69x versus 19.25x for Krystal Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Merck & Co., Inc. has a net margin of 10.18% compared to Ligand Pharmaceuticals, Inc.'s net margin of 33.68%. Ligand Pharmaceuticals, Inc.'s return on equity of 5.72% beat Merck & Co., Inc.'s return on equity of 39.63%.

Ligand Pharmaceuticals, Inc. has a consensus price target of $243.44, signalling upside risk potential of 21.52%. On the other hand Merck & Co., Inc. has an analysts' consensus of $110.04 which suggests that it could grow by 8.85%. Given that Ligand Pharmaceuticals, Inc. has higher upside potential than Merck & Co., Inc., analysts believe Ligand Pharmaceuticals, Inc. is more attractive than Merck & Co., Inc..

Ligand Pharmaceuticals, Inc. has a beta of 1.026, which suggesting that the stock is 2.587% more volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.294, suggesting its less volatile than the S&P 500 by 70.604%.

Ligand Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & Co., Inc. offers a yield of 3.25% to investors and pays a quarterly dividend of $0.85 per share. Ligand Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Merck & Co., Inc. pays out 46.32% of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Ligand Pharmaceuticals, Inc. quarterly revenues are $115.5M, which are smaller than Merck & Co., Inc. quarterly revenues of $17.2B. Ligand Pharmaceuticals, Inc.'s net income of $117.3M is lower than Merck & Co., Inc.'s net income of $5.8B. Notably, Ligand Pharmaceuticals, Inc.'s price-to-earnings ratio is 96.42x while Merck & Co., Inc.'s PE ratio is 13.37x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ligand Pharmaceuticals, Inc. is 15.69x versus 3.99x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.